股票行情快报：祥生医疗（688358）2月2日主力资金净卖出823.24万元

Core Viewpoint - Xiangsheng Medical (688358) experienced a decline in stock price and revenue, indicating potential challenges in the company's financial performance and market position [1]. Financial Performance - As of February 2, 2026, Xiangsheng Medical's stock closed at 34.9 yuan, down 4.7%, with a trading volume of 17,900 hands and a transaction value of 63.8582 million yuan [1]. - For the first three quarters of 2025, the company reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.9205 million yuan, down 4.56% [1]. - The third quarter of 2025 showed a single-quarter main revenue of 107 million yuan, a year-on-year decrease of 6.68%, while the net profit attributable to shareholders increased by 41.95% to 24.2241 million yuan [1]. - The company’s gross profit margin stands at 59.82%, with a debt ratio of 11.24% and investment income of 3.0123 million yuan [1]. Market Activity - On February 2, 2026, the net outflow of main funds was 823.24 thousand yuan, accounting for 12.89% of the total transaction value, while retail investors saw a net inflow of 229.04 thousand yuan, representing 3.59% of the total transaction value [1]. - Over the last 90 days, three institutions have given buy ratings for the stock, indicating a positive outlook from analysts [2].